Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519555 | 0.95 | PNMT (0.46) | PNMTMELK | |
| SCHEMBL4982190 | 0.86 | PPARA (0.45) | ASIC3PNMTHRH3CD274DRD2 | |
| SCHEMBL5256841 | 0.81 | PNMT (0.48) | PNMT | |
| SCHEMBL1076918 | 0.81 | PPARA (0.51) | PNMT | |
| SCHEMBL13962593 | 0.80 | ASIC3 (0.50) | ASIC3PNMTHRH3CD274DRD2 | |
| SCHEMBL12151279 | 0.78 | PPARA (0.53) | HRH3 | |
| SCHEMBL4514738 | 0.77 | PARP11 (0.49) | — | |
| SCHEMBL4518538 | 0.77 | PARP10 (0.49) | DRD2 | |
| Oxalic Acid SCHEMBL7199943 | 0.76 | CD274 (0.52) | ASIC3PNMTHRH3CD274DRD2 | |
| SCHEMBL532484 | 0.75 | CD274 (0.59) | ASIC3PNMTHRH3CD274DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| EP-1979347-A2 | POLYCYCLIC 1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089557-A2 | POLYCYCLIC 1, 2, 3, 4 -TETRAHYDRO- ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | PPARG, PPARD, PPARA | ASIC3 2657/4885PNMT 2445/4885HRH3 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.